On this page
- The placebo-controlled trial
- The inflammation subgroup
- What the reviews contain
- Why COPD is hard to reverse
- What does change outcomes in COPD
- What to be careful of
- How response would have to be measured
- Travel and this condition
- Questions worth asking
- Frequently asked questions
- Requesting a medical evaluation
COPD has been studied with cell therapy in a way that ought to settle the question, and largely does. Stem cell therapy for COPD was tested against placebo in a randomised trial, and the headline finding was that lung function did not improve — which is the kind of result that tells you far more than a dozen positive case series.
The placebo-controlled trial
Mesenchymal cells were tested against placebo in COPD — A placebo-controlled, randomized trial of mesenchymal stem cells in COPD.
This is the study any clinic offering COPD treatment should be asked about, and it rarely appears in their material.
A negative or neutral randomised trial is more informative than a positive uncontrolled series, because it is the design that could have shown a benefit and did not. That is what makes it worth reading.
It also establishes that the question was taken seriously and answered properly, which is not true of most conditions covered on this site.
The inflammation subgroup
A later study looked at lung function specifically in COPD patients with raised C-reactive protein — Effect of mesenchymal stromal cell infusions on lung function in COPD patients with high CRP levels.
Selecting patients by an inflammatory marker is a reasonable scientific move: if the proposed mechanism is anti-inflammatory, then patients with more inflammation are where an effect would show.
It is also, in general, a weaker form of evidence than a primary trial result, because subgroups can be chosen after the fact and will sometimes appear positive by chance.
The honest reading is that this is a hypothesis being refined rather than a treatment being confirmed.
What the reviews contain
A systematic review and meta-analysis of cell administration in COPD describes itself as covering preclinical studies — Preclinical Studies of Mesenchymal Stem Cell (MSC) Administration in Chronic Obstructive Pulmonary Disease (COPD): A Systematic Review and Meta-Analysis.
Preclinical means animal and laboratory work. A systematic review of animal studies is a review of animal studies however impressive its statistics.
This is a recurring pattern across the field: the review that sounds authoritative turns out, on reading the title, to be about mice. What the evidence levels mean covers why that distinction drives the grading here.
Marketing material citing “systematic reviews showing benefit in COPD” is frequently citing this one.
Why COPD is hard to reverse
Emphysema destroys the walls between air sacs, permanently merging them into larger spaces with less surface area for gas exchange. That architecture does not rebuild.
Chronic bronchitis involves airway inflammation and mucus production, which is more modifiable — and is also what existing inhaled treatments target.
Most patients have a mixture, and the destroyed lung tissue is the part that determines long-term outcome. No published treatment restores it.
A treatment might plausibly reduce inflammation or slow decline. That is a different and much smaller claim than restoring lung tissue, and it is the claim the research is actually testing.
What does change outcomes in COPD
Stopping smoking, which is the only intervention that alters the rate of lung function decline.
Pulmonary rehabilitation, which improves exercise capacity and quality of life with strong randomised evidence and is chronically under-used.
Inhaled therapy appropriate to the phenotype, vaccination, and treatment of exacerbations promptly.
Long-term oxygen for those with sustained hypoxaemia, which improves survival. Lung volume reduction and transplant for carefully selected patients.
Nutrition and maintaining muscle mass matter more than most patients are told. Weight loss and muscle wasting in COPD are associated with worse outcomes independently of lung function, and both are partly modifiable.
None of that is a new idea and all of it is available close to home. The gap between these options and what is sold abroad is not a gap in ambition — it is a gap in evidence.
What to be careful of
Claims of lung regeneration. No trial reports it.
Packages combining infusions with nebulised cell or exosome preparations, which add an inhaled route with its own risks and no trial support — exosome therapy covers why that product is graded lowest here.
Improvement measured only by how far someone walked on the day or how they felt, without spirometry before and after.
Any suggestion of reducing or stopping inhaled therapy or oxygen.
How response would have to be measured
Spirometry gives the forced expiratory volume in one second, the standard measure of airflow obstruction, and it is reproducible when properly performed.
A six-minute walk test measures how far someone can walk on the flat in that time and correlates with how they actually function. Both are inexpensive and both are objective.
Symptom questionnaires validated for COPD exist and are used in trials. Between them, these give a picture that does not depend on anyone’s impression.
A treatment offered without any of these performed beforehand cannot be assessed afterwards, whatever is claimed about the result.
Travel and this condition
Significant COPD makes flying harder. Cabin pressure is equivalent to altitude, oxygen levels drop, and people who are stable at sea level can become hypoxaemic in the air.
In-flight oxygen requires assessment and arrangement with the airline in advance, and some patients are advised not to fly at all.
Heat and humidity also affect breathlessness, and Thailand supplies both in quantity.
These practicalities should be discussed before any treatment plan, not after booking. International patients covers what travelling here involves.
Questions worth asking
- What did the placebo-controlled trial in COPD find?
- Will spirometry be done before and after, and by whom?
- Is this an infusion, a nebulised product, or both?
- Have I completed pulmonary rehabilitation?
- Am I fit to fly, and has that been assessed?
Chronic lung conditions covers the wider respiratory picture.
Frequently asked questions
Did the trial show benefit?
The placebo-controlled randomised trial reported no improvement in lung function. That is the headline finding and it is rarely quoted by clinics.
What about the CRP study?
It examined patients selected by raised inflammatory markers. That is a hypothesis being refined, not a treatment being confirmed.
Can damaged lung tissue regrow?
No published trial reports that. Emphysema permanently destroys the walls between air sacs and that architecture does not rebuild.
The systematic review sounded positive.
Check its title. The main review in COPD describes itself as covering preclinical studies — animal and laboratory work.
What actually helps?
Stopping smoking, pulmonary rehabilitation, appropriate inhaled therapy, vaccination, and oxygen where indicated. All have real evidence.
Can I fly with COPD?
It needs assessing. Cabin pressure is equivalent to altitude and people stable at sea level can become short of oxygen in the air.
Requesting a medical evaluation
Nothing on this page establishes whether any treatment is appropriate for you. That needs your history, your imaging and your current medications read by a clinician. If you would like that review, send your records and we will tell you honestly whether there is anything worth discussing — including when the answer is no.
This page is general information, not medical advice, and does not create a doctor–patient relationship. Regenerative treatments discussed here are in most cases investigational. Discuss any treatment with a clinician who knows your history.